| Literature DB >> 34598429 |
Abstract
The pharmacological treatment of COVID-19 has evolved in the months since the description of the disease. Published observational studies and, above all, clinical trials have highlighted drugs that are useful as well as ruled out any benefit from other drugs used at the beginning of the pandemic. The pathogenesis of the disease has suggested that patients may benefit from the administration of both antivirals, mainly in the earliest stages, and anti-inflammatory/immunomodulatory medications in more advanced stages. We present a short review of the drugs used and under investigation for the treatment of COVID-19.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34598429 PMCID: PMC8683015 DOI: 10.37201/req/s01.17.2021
Source DB: PubMed Journal: Rev Esp Quimioter ISSN: 0214-3429 Impact factor: 1.553